Labcorp Holdings Inc LH
News
Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience
LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Labcorp to Speak at the Baird 2024 Global Healthcare Conference
Labcorp Finalizes Acquisition of Select Assets of Invitae
Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx
Labcorp Announces 2024 Second Quarter Results
Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities
Labcorp Declares Quarterly Dividend
Labcorp Gets Emergency Authorization from FDA for Home Kit to Detect Monkeypox